People: Nupathe Inc (PATH.W)
PATH.W on CBOE When Trading NASDAQ Global Select Market
3.10USD
23 May 2013
3.10USD
23 May 2013
Price Change (% chg)
$-0.02 (-0.64%)
$-0.02 (-0.64%)
Prev Close
$3.12
$3.12
Open
$3.10
$3.10
Day's High
$3.10
$3.10
Day's Low
$3.10
$3.10
Volume
200
200
Avg. Vol
351
351
52-wk High
$4.22
$4.22
52-wk Low
$2.60
$2.60
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Wayne Yetter |
2010 | Independent Chairman of the Board | |
Terri Sebree |
53 | 2005 | President |
Armando Anido |
53 | 2012 | Chief Executive Officer, Director |
Keith Goldan |
41 | 2008 | Vice President and Chief Financial Officer |
Gerald McLaughlin |
44 | 2007 | Vice President - Commercial Operations |
Michael Marino |
36 | 2010 | Vice President, General Counsel, Secretary |
Bart Dunn |
53 | 2011 | Vice President - Corporate Development and Licensing |
James Datin |
50 | 2012 | Director |
Richard Kollender |
42 | 2012 | Director |
Brian Sisko |
52 | 2012 | Director |
Michael Cola |
53 | 2010 | Independent Director |
William Federici |
53 | 2011 | Independent Director |
Robert Roche |
56 | 2010 | Independent Director |
Biographies
| Name | Description |
|---|---|
Wayne Yetter |
Mr. Wayne P. Yetter is Independent Chairman of Board of Director of NuPathe Inc. He has served as Chairman of the board of directors of ProActive for Patients Media, Inc., an early investment stage physician-to-patient messaging services company, since October 2009 and also served as its Chief Executive Officer from October 2009 to October 2010. From September 2005 through August 2008, Mr. Yetter served as Chief Executive Officer of Verispan, LLC, a healthcare information company serving pharmaceutical and biotechnology companies. From November 2004 through September 2005, Mr. Yetter served as President and Chief Executive Officer of Odyssey Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr. Yetter also founded Biopharm Advisory, LLC, a healthcare industry advisory firm, and served as its President from July 2003 through September 2005. From September 2003 through November 2004, Mr. Yetter served on the Advisory Board of Alterity Partners, a mergers and acquisition advisory firm. Prior to that, Mr. Yetter served as Chairman and Chief Executive Officer of Synavant, Inc., a customer relationship management and marketing services company focused on the pharmaceutical industry, Chief Operating Officer of IMS, President and Chief Executive Officer of Novartis Pharmaceutical Corp., the U.S. division of Novartis AG, and founding President and Chief Executive Officer of Astra Merck Inc. Previously, Mr. Yetter also served on the board of directors of the following publicly-traded companies: Noven Pharmaceuticals, Inc., where he was Chairman, Synvista Therapeutics, Inc., Transkaryotic Therapies, Inc., where he was Chairman, Maxim Pharmaceuticals, Inc., and Matria Healthcare, Inc., where he was lead independent director. Mr. Yetter also served on the Executive Committee of PhRMA, the pharmaceutical industry association, from 1997 through 1999. Mr. Yetter holds a BA in biology from Wilkes University and an MBA from Bryant University. |
Terri Sebree |
Ms. Terri B. Sebree is President of NuPathe Inc. Prior to founding company, Ms. Sebree served as Senior Vice President, Development of Auxilium Pharmaceutcials, Inc., a specialty pharmaceutical company. Prior to joining Auxilium, Ms. Sebree served as Executive Vice President, U.S. Operations at IBAH, Inc., a multinational contract research organization. Prior to that, Ms. Sebree served in a variety of management roles with Abbott Laboratories for over nine years. Since 2008, Ms. Sebree has served as the Chief Executive Officer of Aerie Africa, a non-profit orphanage in Ethiopia. Ms. Sebree holds a BS from Texas A&M University. |
Armando Anido |
Mr. Armando Anido has been appointed as Chief Executive Officer, Director of NuPathe Inc., effective July 25, 2012. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He is currently a member of the board of directors of Respira Therapeutics and was a member of the board of directors of Adolor until it was sold to Cubist in December 2011. He is the former president and CEO of Auxilium Pharmaceuticals (NASDAQ: AUXL). Prior to Auxilium, Mr. Anido served as executive vice president, sales and marketing, at MedImmune and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At GlaxoWellcome, he was vice president, central nervous system marketing, responsible for the commercialization of the migraine, epilepsy and depression businesses in the U.S. |
Keith Goldan |
Mr. Keith Alan Goldan, CPA, is Vice President and Chief Financial Officer of NuPathe Inc. Previously, Mr. Goldan served as Chief Financial Officer of PuriCore plc, a medical technology company listed on the London Stock Exchange, from October 2004 through October 2008. Mr. Goldan also served as a member of PuriCore's board of directors. Prior to that, Mr. Goldan served as Vice President and Chief Financial Officer of Biosyn, Inc., a specialty pharmaceutical company, and in a variety of roles with ViroPharma Incorporated, Century Capital Associates, a specialty consulting firm with a focus on capital strategy for healthcare clients, and the Healthcare & Life Sciences Practice of KPMG LLP. Mr. Goldan holds a BA from the Robert H. Smith School of Business at the University of Maryland and an MBA from The Wharton School at the University of Pennsylvania. |
Gerald McLaughlin |
Mr. Gerald W. McLaughlin is Vice President - Commercial Operations of NuPathe Inc. Previously, Mr. McLaughlin served in a variety of roles at Endo Pharmaceuticals, a specialty pharmaceutical company, including Senior Director, Strategic Marketing from January 2007 through August 2007, Regional Sales Director from July 2005 through December 2006, Group Marketing Director, Pain Products from November 2002 through June 2005 and Marketing Director. Prior to that, Mr. McLaughlin served in a variety of marketing and sales roles at Merck for 11 years. Mr. McLaughlin holds a BA from Dickinson College and an MBA from Villanova University. |
Michael Marino |
Mr. Michael F. Marino is Vice President, General Counsel, Secretary of NuPathe Inc. Prior to joining NuPathe, Mr. Marino practiced law at the firm of Morgan, Lewis & Bockius LLP from March 2005 to October 2010 and at the firm of WilmerHale LLP from October 2001 to March 2005. While at Morgan, Lewis & Bockius and WilmerHale, Mr. Marino's practice focused on advising life science, technology and other companies on a wide-range of matters, including mergers and acquisitions, securities, finance, corporate governance, compliance and other general corporate matters. Mr. Marino holds a BS in Accountancy from Villanova University and a JD from Boston College School of Law. |
Bart Dunn |
Mr. Bart J. Dunn is Vice President - Corporate Development and Licensing of NuPathe Inc. From August 2006 to June 2011, Mr. Dunn served as Vice President, Business Development & Strategic Planning at Inspire Pharmaceuticals, where he oversaw all corporate development and licensing activities. Prior to that, Mr. Dunn served in a variety of management roles at Pfizer, Inc. for 16 years, including business development, corporate development, strategic planning and financial operations. Mr. Dunn holds a BBA from Pace University, an MBA from St. Joseph's University and is a Certified Public Accountant (CPA). |
James Datin |
Mr. James A. Datin has been appointed as the Director of NuPathe Inc. He is currently Executive Vice President and Managing Director at Safeguard Scientifics, a growth capital provider to life sciences and technology companies. Jim brings to the NuPathe board more than 25 years of experience as a CEO, who has raised capital for entrepreneurs to grow companies, and has turned around troubled companies throughout the United States, Europe and Asia. At Safeguard, Jim leverages this experience to drive partnership opportunities for both life science and technology partner companies, and has earned a multinational track record of success. Prior to Safeguard, Jim was CEO of Touchpoint Solutions; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline (NYSE: GSK); CEO of Isuta Holdings Berhad; and Director, International Business at Baxter International, Inc. (NYSE: BAX) /Merck KGaA. Jim currently serves on the board of directors of NovaSom, Putney, Hepatitis B Foundation, and the University City Science Center. |
Richard Kollender |
Mr. Richard S. Kollender has been appointed as the Director of NuPathe Inc. He is a partner at Quaker Partners, a venture capital and growth equity firm with a focus on the life sciences industry. Prior to joining Quaker Partners in 2003, Richard held positions in sales, marketing and worldwide business development at GlaxoSmithKline. Richard also served as investment manager at S.R. One where he evaluated potential investment opportunities, performed due diligence, structured and negotiated investments and worked with management teams to execute their strategies following investment. Prior to GlaxoSmithKline, Richard was a CPA with KPMG Peat Marwick with an emphasis on the healthcare and emerging businesses sectors. Richard currently serves on the board of directors of Insmed (NASDAQ: INSM), Precision Therapeutics, Rapid Micro Biosystems, and Celator Pharmaceuticals. Richard was previously a member of the board of directors of NuPathe from 2007 to 2011. |
Brian Sisko |
Mr. Brian J. Sisko has been appointed as the Director of NuPathe Inc. He is currently Senior Vice President and General Counsel at Safeguard Scientifics. Brian has over 25 years of experience working with start-up and development-stage companies in various positions, including external legal counsel, internal counsel, executive officer, investor and consultant. Prior to joining Safeguard in 2007, Brian worked with Traffic.com where he was Senior Vice President and General Counsel. Previously, Brian was Chief Operating Officer of Halo Technology Holdings. Prior to that, he held a variety of positions in the venture capital and legal fields. Currently, Brian serves on the board of directors of AdvantEdge Healthcare Solutions, NovaSom, and Penn Mezzanine. |
Michael Cola |
Mr. Michael Cola is Independent Director of NuPathe Inc. From June 2005 to April 2012, Mr. Cola served as President, Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company. Prior to joining Shire, Mr. Cola served as Group President of Safeguard Scientifics, Inc., a holding company for growth stage technology and life sciences companies, and in a variety of positions at AstraZeneca and AstraMerck, including Vice President, Global Clinical Operations. Mr. Cola has also served on the board of directors of Clarient, Inc., a publicly-traded company. He holds MS in biomedical science from Drexel University. Mr. Cola has more than 20 years of international pharmaceutical industry experience. |
William Federici |
Mr. William J. Federici is Independent Director of NuPathe Inc. Mr. Federici has served as Vice President and Chief Financial Officer of West Pharmaceutical Services, Inc., a publicly-traded global manufacturer of components and delivery systems for the pharmaceuticals, healthcare and consumer products industries, since August 2003. From June 2002 until July 2003, he was National Industry Director for Pharmaceuticals of KPMG LLP, a global audit, tax and advisory firm, and prior thereto, an audit partner with Arthur Andersen, LLP. From 2008 to 2009, Mr. Federici served as a director of Synvista Therapeutics, Inc. Mr. Federici is an Advisory Board Member of the Rutgers University School of Business, and a member of the Board of Trustees at Cancer Care of New Jersey. Mr. Federici holds a BA in Economics and an MBA in Professional Accounting from Rutgers University and is a Certified Public Accountant. |
Robert Roche |
Mr. Robert P. Roche, Jr., is Independent Director of Nupathe Inc. Mr. Roche has served as principal of Robert Roche Associates, LLC, a consulting firm focusing on the pharmaceutical and biotechnology industries, since February 2010. From January 1995 through February 2010, Mr. Roche served as the head of commercial operations at Cephalon, Inc., a global biopharmaceutical company. His most recent position at Cephalon, held from February 2005 through February 2010, was Executive Vice President, Worldwide Pharmaceutical Operations, in which capacity he oversaw several new product launches. Prior to that, Mr. Roche served in a variety of sales and marketing positions at SmithKline Beecham, a global pharmaceutical company. Mr. Roche has served on the board of directors of EKR Therapeutics, a privately-held specialty pharmaceutical company, since November 2011, and on the board of directors of Civitas Therapeutics, a privately-held biopharmaceutical company, since January 2012. Previously, Mr. Roche served on the board of directors of LifeCell Corporation, a publicly-traded medical device company focusing on tissue repair products, and from 2008 to 2011, on the board of directors of Intercept Pharmaceuticals, Inc., a privately-held pharmaceutical company focused on metabolic diseases. Mr. Roche currently serves as a Trustee of The Westtown School. Mr. Roche holds a BA in Spanish and history from Colgate University and an MBA from The Wharton School at the University of Pennsylvania. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Wayne Yetter |
-- |
Terri Sebree |
389,414 |
Armando Anido |
-- |
Keith Goldan |
365,825 |
Gerald McLaughlin |
356,680 |
Michael Marino |
315,078 |
Bart Dunn |
-- |
James Datin |
-- |
Richard Kollender |
-- |
Brian Sisko |
-- |
Michael Cola |
-- |
William Federici |
-- |
Robert Roche |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Wayne Yetter |
0 | 0 |
Terri Sebree |
3,119 | 25,295 |
Armando Anido |
0 | 0 |
Keith Goldan |
0 | 0 |
Gerald McLaughlin |
0 | 0 |
Michael Marino |
0 | 0 |
Bart Dunn |
0 | 0 |
James Datin |
0 | 0 |
Richard Kollender |
0 | 0 |
Brian Sisko |
0 | 0 |
Michael Cola |
0 | 0 |
William Federici |
0 | 0 |
Robert Roche |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
YETTER WAYNE P |
13,500 | $0.00 |
COLA MICHAEL F |
13,500 | $0.00 |
KOLLENDER RICHARD S |
13,500 | $0.00 |
FEDERICI WILLIAM J |
13,500 | $0.00 |
ROCHE ROBERT P JR |
13,500 | $0.00 |
QUAKER BIOVENTURES II L P |
2,500,000 | $2.00 |
SAFEGUARD SCIENTIFICS INC |
28,011 | $3.57 |
SAFEGUARD SCIENTIFICS INC |
2,500,000 | $2.00 |
BVP GP L L C |
900,000 | $0.00 |
BVP GP L L C |
100,000 | $0.00 |
ANIDO ARMANDO |
317,580 | $0.00 |
GOLDAN KEITH A |
125,000 | $0.00 |
MARINO MICHAEL F III |
135,000 | $0.00 |
SEBREE TERRI B |
125,000 | $0.00 |
MCLAUGHLIN GERALD W |
125,000 | $0.00 |
MCLAUGHLIN GERALD W |
23,542 | $0.00 |
SEBREE TERRI B |
25,907 | $0.00 |
MARINO MICHAEL F III |
37,500 | $0.00 |
ANIDO ARMANDO |
369,095 | $0.00 |
GOLDAN KEITH A |
28,165 | $0.00 |
SEBREE TERRI B |
11,229 | $0.00 |
GOLDAN KEITH A |
8,109 | $0.00 |
MARINO MICHAEL F III |
21,984 | $0.00 |
MCLAUGHLIN GERALD W |
8,109 | $0.00 |
ANIDO ARMANDO |
116,665 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
